EMT is a reversible biological program in which epithelial cells lose characteristics associated with organized tissue structure and acquire mesenchymal properties. During this transition, cancer cells typically reduce cell-cell adhesion, change shape, become more mobile, and gain greater capacity to invade surrounding tissues. EMT has long been associated with metastasis and treatment resistance, but the molecular factors that connect EMT to improved survival after DNA damage remain incompletely understood.

To search for such factors, the research team used an epigenomic strategy centered on broad regions of trimethylated histone H3 lysine 4, known as H3K4me3. This chromatin modification is commonly associated with active gene promoters. When H3K4me3 domains extend across larger genomic regions, they can mark genes that are particularly important for maintaining cellular identity or controlling major changes in cell behavior. The investigators compared these domains before and after transforming growth factor beta, or TGF-β, induced EMT in lung adenocarcinoma cells.

C/EBPγ emerged from this analysis as a candidate regulator whose chromatin-associated activity increased during EMT. Functional experiments supported that prediction. When researchers introduced C/EBPγ into lung adenocarcinoma cells, the cells developed an elongated, mesenchymal-like appearance, reduced their production of E-cadherin, and increased expression of mesenchymal markers. E-cadherin is a key protein involved in epithelial cell adhesion, and its loss is a widely used molecular indicator of EMT. Cells containing additional C/EBPγ also showed enhanced migratory behavior, whereas depletion of the endogenous protein weakened EMT-associated gene expression and impaired the transition.

The mechanism was notable because C/EBPγ did not require its conventional DNA-binding domain to induce EMT. Instead, the protein depended on its leucine zipper domain, a structural region that enables protein-protein interactions. This result suggests that C/EBPγ functions less as a conventional DNA-binding transcriptional switch and more as a molecular partner that modifies the activity of other regulatory proteins. The distinction is important because it identifies protein-interaction interfaces, rather than only DNA-recognition sites, as potential targets for future therapies.

Proteomic analyses revealed that C/EBPγ interacts with C/EBPβ, another member of the CCAAT/enhancer-binding protein family. In the lung adenocarcinoma models used in the study, C/EBPβ acted as a suppressor of EMT, while C/EBPγ promoted the transition by antagonizing C/EBPβ through leucine zipper-dependent interactions. In this model, the balance between related C/EBP proteins appears to influence whether cancer cells retain epithelial features or adopt a more invasive state. This antagonistic relationship provides a possible explanation for how C/EBPγ can drive EMT without directly binding DNA through its own DNA-binding domain.

The researchers also identified an independent function involving DNA repair. C/EBPγ associated with XRCC5 and XRCC6, two core components of the non-homologous end joining pathway. NHEJ repairs DNA double-strand breaks by bringing broken DNA ends together and rejoining them, often without requiring a long matching sequence between the ends. Although the pathway can introduce small sequence changes, it is essential for rapidly repairing the potentially lethal breaks produced by chemotherapy and other forms of genotoxic stress.

In laboratory experiments, C/EBPγ enhanced NHEJ activity and accelerated the recruitment of XRCC6 to sites of DNA damage. Cells expressing the factor accumulated fewer DNA damage markers after exposure to etoposide, a drug that induces DNA breaks by interfering with topoisomerase II. The findings indicate that C/EBPγ does not merely help cancer cells adopt a more adaptable and mobile phenotype; it also improves their ability to restore damaged chromosomes after treatment.

The consequences were observed in both cell-based assays and mouse xenograft models. Lung adenocarcinoma cells expressing C/EBPγ survived DNA-damaging chemotherapy more efficiently than control cells, and tumors containing the factor were less sensitive to etoposide treatment. When the leucine zipper domain was disrupted, the protective effect was lost, underscoring the importance of C/EBPγ’s interactions with other proteins. The study therefore presents C/EBPγ as a molecular hub that coordinates two features of aggressive disease: EMT-driven cellular plasticity and enhanced repair of therapy-induced DNA damage. Although further work will be needed to determine whether the mechanism operates broadly across patient tumors, disrupting C/EBPγ or its interaction surfaces could eventually provide a way to resensitize lung adenocarcinoma to DNA-damaging treatments.

Subject of Research: C/EBPγ-mediated epithelial-mesenchymal transition, DNA double-strand break repair, and therapy resistance in lung adenocarcinoma

Article Title: C/EBPγ induces epithelial-mesenchymal transition and facilitates DNA double-strand break repair in lung adenocarcinoma cells

News Publication Date: 2 June 2026

Web References: https://doi.org/10.1038/s41420-026-03181-0

References: Cell Death Discovery, DOI: 10.1038/s41420-026-03181-0

Image Credits: Terashima M. et al., Cell Death Discovery (2026), Figure 7F

Keywords: C/EBPγ, lung adenocarcinoma, epithelial-mesenchymal transition, EMT, DNA double-strand breaks, non-homologous end joining, XRCC5, XRCC6, therapy resistance, cancer biology, DNA repair, C/EBPβ

Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, remains a formidable clinical challenge due to its high propensity for metastasis and acquired resistance to conventional DNA-damaging therapies such as radiation and chemotherapy. The biological processes that enable cancer cells to transition from a stationary epithelial state to a mobile mesenchymal form—thereby increasing their metastatic potential—have long been connected to poor prognosis. However, the molecular underpinnings orchestrating this epithelial-mesenchymal transition, especially in the context of DNA damage repair pathways, have been only partially understood until now.

The study rigorously investigated the role of CCAAT/enhancer-binding protein gamma (C/EBPγ), a member of the C/EBP family of transcription factors, widely implicated in cellular differentiation and inflammatory responses. What sets this research apart is its dual focus on how C/EBPγ not only governs phenotypic plasticity through EMT but also actively modulates the DNA repair machinery, particularly the critical repair of DNA double-strand breaks (DSBs). This dual functionality positions C/EBPγ as a potential master regulator in lung adenocarcinoma malignancy and therapy resistance.

Using a combination of molecular biology techniques, including chromatin immunoprecipitation followed by sequencing (ChIP-seq), the researchers mapped the genome-wide binding sites of C/EBPγ in lung adenocarcinoma cell lines. They found that C/EBPγ directly binds to and regulates the promoters of key genes involved in EMT, including those coding for mesenchymal markers such as N-cadherin and vimentin, while repressing epithelial markers like E-cadherin. This transcriptional regulation promotes the cells’ detachment from the primary tumor mass and facilitates their migration and invasion into surrounding tissues.

The discovery did not stop there. Intriguingly, the team observed that cells with elevated C/EBPγ expression exhibited upregulated components of the non-homologous end joining (NHEJ) pathway, the primary mechanism by which most mammalian cells repair DNA double-strand breaks. Enhanced expression of DNA repair proteins like DNA-PKcs and Ku70/80 suggested that C/EBPγ boosts the capacity of cancer cells to withstand genotoxic stress. This finding has significant clinical implications because it hints that C/EBPγ-positive tumors may be intrinsically more resistant to therapies designed to induce lethal DNA breaks.

Functional assays confirmed these observations: knocking down C/EBPγ in lung adenocarcinoma cells led to impaired EMT, reduced migratory abilities, and a marked decrease in the efficiency of DNA DSB repair after radiation treatment. Conversely, overexpression of C/EBPγ accelerated EMT and conferred resistance to DNA-damaging agents, underscoring its potential as a prognostic marker and therapeutic target.

At the molecular level, the interaction between C/EBPγ and other key transcription factors was also probed. The study highlighted how C/EBPγ cooperates with Snail and Twist, two well-known EMT-inducing factors, forming a transcriptional network that amplifies the mesenchymal gene expression program. This cooperation extends to the regulation of DNA repair genes, illustrating a complex crosstalk between the phenotypic plasticity of cancer cells and their genomic maintenance systems.

Another fascinating aspect uncovered by the research involves the epigenetic landscape. C/EBPγ was shown to recruit chromatin remodeling complexes to EMT and DNA repair gene loci, facilitating an open chromatin state conducive to active transcription. These epigenetic modifications further stabilize the mesenchymal state and reinforce the capacity for DNA repair, making cancer cells more adaptable and resilient.

The clinical relevance of these findings was bolstered by analyses of patient-derived lung adenocarcinoma samples. Higher levels of C/EBPγ correlated with advanced tumor stages, increased metastasis, and poorer overall survival, underscoring the translational potential of targeting this factor. Moreover, the research team suggested that pharmacological inhibition of C/EBPγ or its downstream effectors might sensitize tumors to DNA-damaging therapies, paving the way for novel combination treatments.

From a therapeutic standpoint, this study opens intriguing possibilities. Inhibitors designed to disrupt the function or expression of C/EBPγ could not only prevent EMT-mediated metastasis but also cripple the DNA repair defenses of cancer cells, rendering them vulnerable to radiation and chemotherapy. Such dual-action therapeutics would represent a paradigm shift, addressing both the invasive capacity and therapeutic resistance of lung cancer.

Furthermore, the insights gained about C/EBPγ’s interactions with chromatin remodeling complexes and transcriptional networks provide promising avenues for drug discovery. Epigenetic modulators that reverse the chromatin changes induced by C/EBPγ may complement direct inhibitors, creating multi-pronged strategies to thwart cancer progression.

This research also raises provocative questions for future exploration. For instance, understanding how C/EBPγ expression is regulated within the tumor microenvironment or by oncogenic signaling pathways could illuminate the signals that drive aggressive phenotypes. Additionally, it prompts investigation into whether similar mechanisms operate in other cancer types, potentially broadening the impact of these findings.

In summary, the identification of C/EBPγ as a critical driver of both epithelial-mesenchymal transition and enhanced DNA double-strand break repair pathways presents a significant advance in lung adenocarcinoma biology. It links cellular plasticity directly with genomic stability strategies, underscoring the adaptability of cancer cells and highlighting a crucial vulnerability.

As lung adenocarcinoma continues to challenge clinicians with its aggressive nature and resistance to conventional therapies, these findings illuminate new molecular targets and strategies. The prospect of therapies that can simultaneously inhibit metastasis and sensitize tumors to DNA damage could revolutionize patient outcomes, transforming lung cancer from a largely intractable disease into one that can be effectively managed or even cured.

Given the compelling data presented and the potential clinical applications, this study is poised to stimulate extensive research and drug development efforts aimed at exploiting C/EBPγ’s dual role. It heralds a future where the genetic and phenotypic malleability of lung adenocarcinoma cells can be manipulated for therapeutic benefit, greatly enhancing the arsenal against one of the most lethal human cancers.

Subject of Research:
Role of C/EBPγ in inducing epithelial-mesenchymal transition and facilitating DNA double-strand break repair in lung adenocarcinoma cells.

Article Title:
C/EBPγ induces epithelial-mesenchymal transition and facilitates DNA double-strand break repair in lung adenocarcinoma cells.

Article References:
Terashima, M., Suzuki, R., Suphakhong, K. et al. C/EBPγ induces epithelial-mesenchymal transition and facilitates DNA double-strand break repair in lung adenocarcinoma cells. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03181-0

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41420-026-03181-0